Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1980
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 1
1988 1
1990 2
1991 1
1992 1
1993 3
1995 2
1996 1
1997 4
1998 3
1999 2
2000 5
2001 2
2002 5
2003 13
2004 10
2005 10
2006 14
2007 18
2008 19
2009 15
2010 30
2011 23
2012 19
2013 23
2014 39
2015 31
2016 31
2017 30
2018 22
2019 23
2020 25
2021 25
2022 34
2023 45
2024 36
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

521 results

Results by year

Filters applied: . Clear all
Page 1
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis.
Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Wong WL, et al. Lancet Glob Health. 2014 Feb;2(2):e106-16. doi: 10.1016/S2214-109X(13)70145-1. Epub 2014 Jan 3. Lancet Glob Health. 2014. PMID: 25104651 Free article. Review.
METHODS: We did a systematic literature review to identify all population-based studies of age-related macular degeneration published before May, 2013. Only studies using retinal photographs and standardised grading classifications (the Wisconsin ag
METHODS: We did a systematic literature review to identify all population-based studies of age-related macular degen
Age-Related Macular Degeneration.
Thomas CJ, Mirza RG, Gill MK. Thomas CJ, et al. Med Clin North Am. 2021 May;105(3):473-491. doi: 10.1016/j.mcna.2021.01.003. Epub 2021 Apr 2. Med Clin North Am. 2021. PMID: 33926642 Free article. Review.
Age-related macular degeneration (AMD) is a leading cause of blindness. The main risk factor is advancing age, with the severity of vision loss ranging from mild to severe. There is a 25% risk of early AMD and 8% risk of late AMD in patie
Age-related macular degeneration (AMD) is a leading cause of blindness. The main risk factor is advancing age
Treatment of dry age-related macular degeneration: A review.
Girgis S, Lee LR. Girgis S, et al. Clin Exp Ophthalmol. 2023 Nov;51(8):835-852. doi: 10.1111/ceo.14294. Epub 2023 Sep 22. Clin Exp Ophthalmol. 2023. PMID: 37737509 Review.
Age-related macular degeneration is a global disease with a significant societal impact. The advent of anti-vascular endothelial growth factor therapy (anti-VEGF) has revolutionised the treatment of neovascular age-related macular
Age-related macular degeneration is a global disease with a significant societal impact. The advent of anti-vasc
The electrooculogram.
Creel DJ. Creel DJ. Handb Clin Neurol. 2019;160:495-499. doi: 10.1016/B978-0-444-64032-1.00033-3. Handb Clin Neurol. 2019. PMID: 31277871 Review.
The voltage becomes smaller in the dark, reaching its lowest potential after 8-12min, the so-called dark trough. When the lights are turned on, the potential rises, reaching a peak by about 10min. ...
The voltage becomes smaller in the dark, reaching its lowest potential after 8-12min, the so-called dark trough. When the lights are …
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets.
Chen X, Shi C, He M, Xiong S, Xia X. Chen X, et al. Signal Transduct Target Ther. 2023 Sep 15;8(1):352. doi: 10.1038/s41392-023-01570-w. Signal Transduct Target Ther. 2023. PMID: 37709773 Free PMC article. Review.
Accumulated data indicates its key role in protein homeostasis and other diverse functions involved in various ocular diseases, such as glaucoma, diabetic retinopathy, age-related macular degeneration, retinitis pigmentosa, achromatopsia, cataracts, oc …
Accumulated data indicates its key role in protein homeostasis and other diverse functions involved in various ocular diseases, such as glau …
PINK1/PARKIN signalling in neurodegeneration and neuroinflammation.
Quinn PMJ, Moreira PI, Ambrósio AF, Alves CH. Quinn PMJ, et al. Acta Neuropathol Commun. 2020 Nov 9;8(1):189. doi: 10.1186/s40478-020-01062-w. Acta Neuropathol Commun. 2020. PMID: 33168089 Free PMC article. Review.
We will continue by debating the role of mitochondrial dysfunction in disorders such as amyotrophic lateral sclerosis, Alzheimer's, Huntington's and Parkinson's diseases, as well as eye diseases such as age-related macular degeneration and glaucoma, an …
We will continue by debating the role of mitochondrial dysfunction in disorders such as amyotrophic lateral sclerosis, Alzheimer's, Huntingt …
Ranibizumab.
Blick SK, Keating GM, Wagstaff AJ. Blick SK, et al. Drugs. 2007;67(8):1199-206; discussion 1207-9. doi: 10.2165/00003495-200767080-00007. Drugs. 2007. PMID: 17521219 Review.
Well designed, phase III trials in patients with neovascular (wet) age-related macular degeneration (AMD) indicated that monthly intravitreal injections of ranibizumab 0.3 or 0.5 mg for up to 2 years maintained or improved visual acuity to a greater ex …
Well designed, phase III trials in patients with neovascular (wet) age-related macular degeneration (AMD) indica …
Current Treatments for Diabetic Macular Edema.
Tatsumi T. Tatsumi T. Int J Mol Sci. 2023 May 31;24(11):9591. doi: 10.3390/ijms24119591. Int J Mol Sci. 2023. PMID: 37298544 Free PMC article. Review.
Neuronal cell death and axonal degeneration are irreversible, and their development can result in permanent visual loss. ...This review describes the effective treatments for the macular edema that are therefore neuroprotective....
Neuronal cell death and axonal degeneration are irreversible, and their development can result in permanent visual loss. ...This revi …
Global causes of blindness and distance vision impairment 1990-2020: a systematic review and meta-analysis.
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, Das A, Jonas JB, Keeffe J, Kempen JH, Leasher J, Limburg H, Naidoo K, Pesudovs K, Silvester A, Stevens GA, Tahhan N, Wong TY, Taylor HR; Vision Loss Expert Group of the Global Burden of Disease Study. Flaxman SR, et al. Lancet Glob Health. 2017 Dec;5(12):e1221-e1234. doi: 10.1016/S2214-109X(17)30393-5. Epub 2017 Oct 11. Lancet Glob Health. 2017. PMID: 29032195 Free article. Review.
Among the global population with moderate or severe vision impairment in 2015 (216.6 million [80% uncertainty interval 98.5 million to 359.1 million]), the leading causes were uncorrected refractive error (116.3 million [49.4 million to 202.1 million]), cataract (52.6 million [18 …
Among the global population with moderate or severe vision impairment in 2015 (216.6 million [80% uncertainty interval 98.5 million to 359.1 …
Complement inhibitors for age-related macular degeneration.
Tzoumas N, Riding G, Williams MA, Steel DH. Tzoumas N, et al. Cochrane Database Syst Rev. 2023 Jun 14;6(6):CD009300. doi: 10.1002/14651858.CD009300.pub3. Cochrane Database Syst Rev. 2023. PMID: 37314061 Free PMC article. Review.
BACKGROUND: Age-related macular degeneration (AMD) is a common eye disease and leading cause of sight loss worldwide. ...The incidence of endophthalmitis in patients treated with monthly and EOM pegcetacoplan was 6 per 1000 (1 to 53) and 8 per 1 …
BACKGROUND: Age-related macular degeneration (AMD) is a common eye disease and leading cause of sight loss world …
521 results